| 4LMN: reference: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, Ludlam MJ, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M, Nature. 2013 Aug 11. doi: 10.1038/nature12441. PMID: 23934108 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).